Мировой рынок устройств нейромодуляции – тенденции отрасли и прогноз до 2031 года

Анализ и размер рынка устройств нейромодуляции

Рост распространенности болезни Паркинсона в мире является одним из основных факторов, способствующих росту рынка. Растущее внимание к технологическим достижениям в здравоохранении в сочетании с увеличением числа клинических испытаний является еще одним фактором, определяющим рост рынка. Рост медицинского туризма и всплеск одобрения нейростимуляторов будут и дальше генерировать прибыльные возможности для роста рынка.

Однако высокие затраты, связанные с оборудованием, будут сдерживать темпы роста рынка. Нехватка медицинских экспертов и неблагоприятная политика возмещения расходов, особенно в развивающихся и слаборазвитых экономиках, будут еще больше создавать проблемы для рынка. Кроме того, неосведомленность в отсталых экономиках и низкие показатели диагностики и лечения в развивающихся экономиках будут сдерживать темпы роста рынка.             

Data Bridge Market Research анализирует, что глобальный рынок устройств нейромодуляции, который в 2023 году составил 6,7 млрд долларов США, к 2031 году, скорее всего, достигнет 16,37 млрд долларов США и, как ожидается, будет претерпевать среднегодовой темп роста в 11,80% в течение прогнозируемого периода. «Внутренняя нейромодуляция» доминирует в сегменте типов продуктов на рынке, поскольку внутренняя нейромодуляция обеспечивает прочность и выносливость. Помимо информации о рыночных сценариях, таких как рыночная стоимость, темпы роста, сегментация, географический охват и основные игроки, рыночные отчеты, курируемые Data Bridge Market Research, также включают глубокий экспертный анализ, эпидемиологию пациентов, анализ конвейера, анализ цен и нормативную базу.

Объем и сегментация рынка устройств нейромодуляции

Определение рынка

Устройства для нейромодуляции — это медицинские инструменты, которые используются в процессе нейромодуляции, который использует электричество или химические вещества в организме для стимуляции неврологических участков. Нейромодуляция используется для лечения широкого спектра неврологических заболеваний, таких как эпилепсия, болезнь Альцгеймера , цереброваскулярные заболевания и болезнь Паркинсона.

Динамика мирового рынка устройств нейромодуляции

Драйверы

• Рост распространенности хронических заболеваний

Рост заболеваемости хроническими заболеваниями, такими как хроническая боль, неврологические расстройства и двигательные расстройства, является существенным драйвером для рынка. Нейромодуляционная терапия, включая стимуляцию спинного мозга и глубокую стимуляцию мозга , предлагает альтернативные варианты лечения для пациентов, которые могут не поддаваться традиционным фармацевтическим подходам.

• Достижения в области технологий нейромодуляции

Продолжающиеся исследования и разработки в области технологий нейромодуляции способствуют росту рынка. Инновации в дизайне устройств, электродных технологиях и параметрах стимуляции повышают эффективность и безопасность нейромодуляционной терапии. Достижения могут привести к разработке более целенаправленных и точных устройств, расширяя спектр излечимых состояний.

• Повышение осведомленности и принятия нейромодуляционной терапии

Growing awareness among both healthcare professionals and patients about the benefits of neuromodulation therapies contributes to market expansion. As more clinical evidence supports the efficacy and safety of these therapies, acceptance among physicians and patients is likely to increase. Patient education initiatives and collaborations between healthcare providers and device manufacturers also play a role in promoting the adoption of neuromodulation devices.

• Growing Investment for Healthcare Facilities

Surging focus on improving the condition of healthcare facilities and improving the overall healthcare infrastructure is another important factor fostering the growth of the market. The rising number of partnerships and strategic collaborations between the public and private players about funding and application of new and improved technology is further creating lucrative market opportunities.  

Opportunities

• Expanding Applications and Indications

There is an opportunity to explore and develop new applications and indications for neuromodulation devices. As the understanding of neural circuitry and the mechanisms of various disorders improves, neuromodulation therapies can be adapted for a broader range of conditions. Research and development efforts that expand the scope of neuromodulation to address conditions beyond chronic pain, such as psychiatric disorders and autoimmune diseases, could open new markets and revenue streams.

• Technological Innovations and Miniaturization

Continued advancements in technology, including miniaturization and the development of more sophisticated and targeted devices, present opportunities in the neuromodulation devices market. Smaller, implantable devices with enhanced capabilities may lead to increased patient acceptance, improved outcomes, and expanded applications. Innovations such as closed-loop systems that provide adaptive, real-time adjustments based on physiological feedback offer promising prospects for more effective and personalized treatments.

Restraints

• High Cost of Neuromodulation Devices

The cost of neuromodulation devices, including the initial implantation procedure and ongoing maintenance, can be substantial. This poses a challenge for widespread adoption, especially in regions with limited healthcare budgets or where reimbursement policies may not adequately cover the expenses. The high cost can be a barrier to access for some patients and limit market growth.

• Stringent Regulatory Approval Processes

The regulatory approval process for neuromodulation devices is often stringent and time-consuming. Obtaining approvals from regulatory authorities such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) involves extensive clinical trials and data submission. Delays in obtaining approvals can hinder the timely introduction of new devices to the market, affecting innovation and competitiveness.

Challenges

• Risk of Adverse Events and Complications

Neuromodulation procedures, like any surgical intervention, carry inherent risks of adverse events and complications. These may include infection, device malfunction, or unintended side effects. Concerns about the safety and long-term outcomes of neuromodulation therapies can impact patient and physician confidence, potentially leading to hesitancy in adopting these treatments.

• Limited Awareness and Understanding

Despite the potential benefits of neuromodulation therapies, there is often limited awareness and understanding among patients and even some healthcare professionals. This lack of awareness can result in underdiagnosis and underutilization of neuromodulation devices for treating certain conditions. Educational efforts are needed to increase awareness about the efficacy, safety, and appropriateness of neuromodulation therapies for various disorders.

This neuromodulation devices market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the neuromodulation devices market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In September 2023, PathMaker Neurosystems Inc. started a human clinical trial for its MyoRegulator device developed for the treatment of amyotrophic lateral sclerosis (ALS)
• In July 2023, Slavia BioElectronics reported the first implantation of its paper-thin neuromodulation bioelectronic foils for the treatment of severe migraine and cluster headaches

Global Neuromodulation Devices Market Scope

The neuromodulation devices market is segmented on the basis of product type, end user, application and biomaterial. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product Type

• Internal Neuromodulation
• External Neuromodulation

Application                                                                     

• Spinal Cord Stimulation
• Deep Brain Stimulation
• Sacral Nerve Stimulation
• Vagus Nerve Stimulation
• Gastric Electrical Stimulation
• Transcutaneous Electrical Nerve Stimulation
• Repetitive Transcranial Magnetic Stimulation
• Respiratory Electrical Stimulation

End user

• Hospitals
• Clinics
• Home Healthcare
• Others

Biomaterial

• Metallic Biomaterials
• Polymeric Biomaterials
• Ceramic Biomaterials

Global Neuromodulation Devices Market Regional Analysis/Insights

The neuromodulation devices market is analyzed and market size insights and trends are provided by country, product type, end user, application and biomaterial as referenced above.

The countries covered in the market report are the U.S., Canada, Mexico, Germany, U.K., France, Italy, Spain, Russia, Poland, Switzerland, Netherlands, Hungary, Austria, Norway, Ireland, Turkey, Lithuania, rest of Europe, China, Japan, India, Australia, South Korea, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, rest of Asia-Pacific, Brazil, Argentina, Peru, rest of South America, South Africa, Saudi Arabia, U.A.E., Israel, Egypt, and rest of Middle East & Africa.

North America is expected to dominate the market due to the prevalence of favourable reimbursement policies. Asia-Pacific is expected to exhibit the highest growth rate during the forecast period due to the growth and expansion of healthcare industry in this region, ever-rising geriatric population and growth in the number of neurological disorders.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Healthcare Infrastructure growth Installed base and New Technology Penetration

The neuromodulation devices market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for neuromodulation devices market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the neuromodulation Devices market. The data is available for historic period 2010-2020.

Competitive Landscape and Global Neuromodulation Devices Market Share Analysis

The neuromodulation devices market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to neuromodulation devices market.

Some of the major players operating in the neuromodulation devices market are:

• Medtronic (Ireland)
• Boston Scientific Corporation (U.S.)
• Stryker (U.S.)
• Abbott (U.S.)
• Б. Браун Мельсунген АГ (Германия)
• NEVRO CORP. (США)
• NeuroSigma, Inc. (США)
• NeuroPace, Inc. (США)
• Soterix Medical Inc. (США)
• Synapse Biomedical Inc. (США)
• ReShape Lifesciences, Inc. (США)
• Bioness Inc. (США)
• ALEVA NEUROTHERAPEUTICS SA (Швейцария)
• LivaNova PLC (Великобритания)
• Нейронетика. (США)
• Cyberonics, Inc. (США)
• Нейромод (Ирландия)
• Axonics, Inc. (США)
• Magstim Company Limited (Великобритания)
• Sooma Medical (Финляндия)

SKU-47959